MedTrace Logo

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2012-09-12

Study results available
· View outcomes & findings →

Summary

Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

DRUG

Tazarotene Cream 0.1%

1 pea-size amount, QD x 16 weeks

DRUG

Adapalene

1 pea-size amount, QD x 16 weeks

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829049 on ClinicalTrials.gov